Stay updated with breaking news from Stevee Krognes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective dropped by analysts at UBS Group from $70.00 to $32.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s price objective suggests a potential upside of 65.29% from […]
Profund Advisors LLC lowered its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 13.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 40,154 shares of the company’s stock after selling 6,321 shares during the quarter. Profund Advisors LLC’s holdings in Denali Therapeutics […]
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Steve E. Krognes sold 2,750 shares of the company’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $47,547.50. Following the completion of the transaction, the director now directly owns 139,841 shares […]
Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) Director Steve E. Krognes sold 3,208 shares of the firm’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $19.43, for a total transaction of $62,331.44. Following the transaction, the director now directly owns 142,591 shares in the company, […]
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have earned a consensus rating of “Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued ratings on the stock […]